Poor
Needs Major Revision
Patient Risk:
Medium
Summary
Major discrepancies versus the provided FDA label include incorrect active ingredient composition (high severity). Multiple additional claims are unsupported or misrepresented (e.g., effectiveness percentages and adverse effect frequency/detail) based on the supplied label excerpts.
Category Scores
Accurate Statements
Phexxi is a vaginal gel used to prevent pregnancy.
Supported by INDICATIONS AND USAGE (1) and DESCRIPTION (11).
Phexxi works by creating a more acidic environment in the vagina.
Supported by MECHANISM OF ACTION (12.1).
Phexxi reduces sperm motility.
Supported by MECHANISM OF ACTION (12.1) (sperm motility reduction).
Unsupported Statements
The increased vaginal acidity is inhospitable to sperm.
Label excerpt supports acidic pH range and post-coital testing with sperm motility reduction, but the exact phrasing 'inhospitable to sperm' is not explicitly stated in the provided sections.
Phexxi reduces sperm ability to fertilize an egg.
Not explicitly supported by the provided label excerpts.
Common side effects of Phexxi include vaginal discomfort such as burning or itching.
Adverse reaction details are not provided in the supplied label sections.
Common side effects of Phexxi include increased vaginal discharge.
Adverse reaction details are not provided in the supplied label sections.
Some users may experience headaches with Phexxi use.
Adverse reaction details are not provided in the supplied label sections.
Some users may experience a burning sensation during intercourse with Phexxi use.
Adverse reaction details are not provided in the supplied label sections.
Serious side effects of Phexxi are rare.
No severity/rarity statements for serious adverse effects are present in the supplied label sections.
Serious side effects of Phexxi can include allergic reactions.
The supplied excerpts do not characterize allergic reactions as 'serious side effects' or provide that framing/list.
In clinical trials, Phexxi had an effectiveness rate of 86% with typical use.
The provided CLINICAL STUDIES excerpt does not contain a '86% typical use effectiveness' statement.
With typical use, 14 out of 100 users became pregnant over one year with Phexxi.
The provided CLINICAL STUDIES excerpt provides a 7-cycle cumulative pregnancy rate (13.7%) but does not state 'over one year' or '14 out of 100' phrasing.
With perfect use, Phexxi had an effectiveness rate of 97.5%.
No perfect-use effectiveness percentage is provided in the supplied CLINICAL STUDIES excerpt.
With perfect use, fewer than 3 out of 100 users became pregnant over one year with Phexxi.
No perfect-use analysis and no 'over one year' statement are provided in the supplied excerpt.
Phexxi is a non-hormonal contraceptive option.
The supplied label excerpts do not explicitly state 'non-hormonal'.
Phexxi is manufactured by Evofem Biosciences.
No manufacturer information is included in the supplied label excerpts.
Phexxi can be purchased through pharmacies.
No distribution/retail access information is included in the supplied label excerpts.
Phexxi can be purchased through online retailers.
No distribution/retail access information is included in the supplied label excerpts.
Patients can obtain Phexxi directly from their healthcare provider.
The patient counseling excerpt addresses administration/consultation but does not specify how patients obtain the product.
Contradictions
High
AI Statement
The active ingredients of Phexxi are lactic acid, sodium hydroxide, and citric acid.
Label Reference
DESCRIPTION (11) states active ingredients are lactic acid, citric acid, and potassium bitartrate; sodium hydroxide is an inactive ingredient.
High
AI Statement
Lactic acid, sodium hydroxide, and citric acid collectively lower vaginal pH.
Label Reference
DESCRIPTION (11) indicates sodium hydroxide is inactive and potassium bitartrate is active; MECHANISM OF ACTION (12.1) describes pH effects without attributing them to sodium hydroxide.
Important Omissions
The label’s on-demand dosing/administration instructions (e.g., timing before intercourse, additional dose if intercourse does not occur within one hour) were not claimed in the provided AI extraction.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Incorrect identification of active ingredients and attribution of pH-lowering to an inactive ingredient conflicts with the provided label description, which could materially misinform users/clinicians. Multiple other claims about efficacy and adverse effects are unsupported by the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Needs Major Revision
Primary Issue
Incorrect active ingredient list and incorrect attribution of pH effects to sodium hydroxide (inactive ingredient per label).
Suggested Improvement
Replace active ingredient composition and pH-mechanism attribution with label-supported active ingredients (lactic acid, citric acid, potassium bitartrate) and limit efficacy and adverse reaction statements to values and descriptions explicitly present in the provided FDA label excerpts.